Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme

Andrea Gori, Manuela Doroana, Oksana Chernova, Jürgen K. Rockstroh, Denes Banhegyi, Colm Bergin, Gabriella Verucchi, Chris Liu, Ralph DeMasi, Blanca Hadacek, Mark Nelson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV. Results: Mean age was 44 years, 97/118 patients were male and all were Caucasian, 68 had severe fibrosis and 50 had cirrhosis. Seventy-eight had HCV RNA levels ≥800 000 IU/mL, 72 had HCV genotype 1a, baseline HIV RNA was <50 copies/mL in 112 patients. Overall, 114/118 patients continued antiretroviral treatment, 4 were untreated. Seventy-five patients received tenofovir and 74 emtricitabine; in addition 53 received atazanavir/ritonavir, 43 raltegravir, and 24 efavirenz. By intention-to-treat, 78 (66%) patients achieved SVR24. Nineteen discontinued telaprevir, 8 for virological endpoint, 5 for adverse events (2 anaemia, 2 rash, 1 asthenia), 5 for non-compliance and 1 withdrew consent. The most common adverse events were anaemia (36 patients), thrombocytopaenia (33), rash (26), bilirubin increase (17), and neutropenia (16). Conclusions: In this early access programme in coinfected patients with severe fibrosis or cirrhosis, 66% of patients achieved SVR. The most common adverse events were haematological. Clinical Trial Number: NCT01500616.

Original languageEnglish
Pages (from-to)675-682
Number of pages8
JournalJournal of Infection
Volume71
Issue number6
DOIs
Publication statusPublished - Dec 2015

Keywords

  • Bridging fibrosis
  • Cirrhosis
  • Coinfection
  • HIV
  • Hepatitis C
  • Telaprevir

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme'. Together they form a unique fingerprint.

  • Cite this

    Gori, A., Doroana, M., Chernova, O., Rockstroh, J. K., Banhegyi, D., Bergin, C., Verucchi, G., Liu, C., DeMasi, R., Hadacek, B., & Nelson, M. (2015). Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme. Journal of Infection, 71(6), 675-682. https://doi.org/10.1016/j.jinf.2015.09.013